Is the FDA as lenient as everyone thinks? Can fish oil be a multibillion-dollar drug? And why aren’t there better treatments for brain cancer?

We discuss all that and more in the latest episode of “The Readout LOUD,” STAT’s biotech podcast. Tune in for a conversation about how a recent FDA rejection flies in the face of what had become conventional wisdom in the drug industry. Then we’ll talk about how the immunotherapy revolution in oncology has done little for glioblastoma, the cancer that killed Sen. John McCain. We’ll also dig into how a major trial on the cardiovascular benefits of fish oil could be a bad omen for Amarin and its efforts to turn a marginal product into a blockbuster. Finally, we’ll embark on a lightning round, covering the slow process of socialized medicine, the summer homes of sell-side analysts, and the future of digital medicine.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy